Co-administration of 5α-reductase Inhibitors Worsens the Adverse Metabolic Effects of Prescribed Glucocorticoids
- 1 September 2020
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (9), e3316-e3328
- https://doi.org/10.1210/clinem/dgaa408
Abstract
Context Glucocorticoids (GC) are commonly prescribed, but their use is associated with adverse metabolic effects. 5a-reductase inhibitors (5aRI) are also frequently prescribed, mainly to inhibit testosterone conversion to dihydrotestosterone. However, they also prevent the inactivation of GCs. Objective We hypothesised that 5aRIs may worsen the adverse effects of GCs. Design Prospective, randomised study. Patients 19 healthy male volunteers (age; 45±2 years, BMI; 27.1±0.7kg/m2). Interventions Participants underwent metabolic assessments; 2-step hyperinsulinemic, euglycemic clamp incorporating stable-isotopes, adipose tissue microdialysis and biopsy. Participants were then randomised to either prednisolone (10mg daily) or prednisolone (10mg daily) plus a 5aRI (finasteride 5mg daily or dutasteride 0.5mg daily) for 7 days; metabolic assessments were then repeated. Main Outcome Measures Ra glucose, glucose utilization (M-value), glucose oxidation, non-esterified fatty acids (NEFA) levels. Results Co-administration of prednisolone with a 5aRI increased circulating prednisolone levels (482±96 vs. 761±57nmol/L, p=0.029). Prednisolone alone did not alter Ra glucose (2.55±0.34 vs 2.62±0.19mg/kg/min, p=0.86), M-value (3.2±0.5 vs 2.7±0.7mg/kg/min, p=0.37), or glucose oxidation (0.042±0.007 vs 0.040±0.004mmol/hr/kg/min, p=0.79). However, co-administration with a 5aRI increased Ra glucose (2.67±0.16 vs. 3.05±0.18mg/kg/min, pvs. 2.6±0.4mg/kg/min, pvs. 0.036±0.002mmol/hr/kg, pvs. 36.8±14.3μmol/L, p=0.81), unless co-administered with a 5aRI (49.8±8.6 vs. 88.5±13.5μmol/L, p<0.01). Conclusions We have demonstrated that 5aRIs exacerbate the adverse effects of prednisolone. This study has significant translational implications, including the need to consider GC dose adjustments, but also the necessity for increased vigilance for the development of adverse effects.Keywords
Funding Information
- National Institute for Health Research
- Medical Research Council (MR/P011462/1)
- British Heart Foundation (FS/15/56/31645)
- University of Oxford
- Novo Nordisk
This publication has 39 references indexed in Scilit:
- Improved workflows for high throughput library preparation using the transposome-based nextera systemBMC Biotechnology, 2013
- Inhaled corticosteroid use in HIV‐positive individuals taking protease inhibitors: a review of pharmacokinetics, case reports and clinical managementHIV Medicine, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- GENCODE: The reference human genome annotation for The ENCODE ProjectGenome Research, 2012
- Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trialDiabetologia, 2011
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression dataBioinformatics, 2009
- Impaired Glucose Tolerance and Insulin Resistance Are Associated With Increased Adipose 11β-Hydroxysteroid Dehydrogenase Type 1 Expression and Elevated Hepatic 5α-Reductase ActivityDiabetes, 2008
- Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literatureHIV Medicine, 2008
- Reduced Glucocorticoid Production Rate, Decreased 5α-Reductase Activity, and Adipose Tissue Insulin Sensitization After Weight LossDiabetes, 2008
- Use of oral corticosteroids in the United KingdomQJM: An International Journal of Medicine, 2000